Source: Eur Respir J 2002; 19: 294-302



Rating:

Share or cite this content

Citations should be made in the following way:
App E.M., Baran D., Dab I., Malfroot A., Coffiner M., Vanderbist F., King M.. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J 2002; 19: 294-302

Member's Comments

No comment yet.

Related content which might interest you: Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006 Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice Source: Eur Respir J 2011; 37: 72-78 Year: 2011 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis Source: Eur Respir J 2001; 18: 316-322 Year: 2001 Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017 Pharmacological airway clearance strategies in bronchiectasis Source: Eur Respir Mon 2011; 52: 239-247 Year: 2011 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Inhaled heparin in cystic fibrosis Source: Eur Respir J 2006; 27: 354-358 Year: 2006 Nebulised 7 % hypertonic sodium chloride improves lung function and airway clearance in non cystic fibrosis bronchiectasis Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Long-term clearance from small airways in patients with cystic fibrosis Source: Eur Respir J 2005; 25: 317-323 Year: 2005 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Source: Eur Respir J 2015; 45: 428-439 Year: 2015 Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis}, Source: Eur Respir J 2012; 40: 969-976 Year: 2012 Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition Source: ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018 Year: 2019 Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Lung function parameters influence serum concentration after antibiotic inhalation in patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 537s Year: 2001